This is the latest installment in a series where BioPharma Dive uses data visualization to recap what’s going on across the industry. Today, we’re looking at a series of acquisitions and IPOs involving China-linked drug startups and Summit Therapeutics’ stock performance.
The burst of dealmaking involving drugs from China isn’t just causing consternation among U.S. lawmakers and sparking spirited debate between biotech veterans. It’s also altering the venture capital playbook.
Biotech venture firms have historically incubated and built companies around early research that takes time — often many years — to yield a drug. But the availability in China of a trove of medicines has given investors a way to compress that process. Over the last few years, an array of new startups has been assembled around China-originated medicines either in or nearing human testing. Investors have piled into these kinds of companies, hiring experienced executive teams to lead development and propel them toward the public markets.
Many of these bets have already paid off. This year alone, three of these young startups — Ouro Medicines, Candid Therapeutics and, on Monday, Ollin Biosciences — have been acquired in billion-dollar deals. Three more have priced initial public offerings, among them an obesity drugmaker called Kailera Therapeutics that temporarily held a sector record. Several others like Serapha Bio and Caldera Therapeutics have used alternate paths to quickly get to Wall Street.
Some of these deals are occurring extraordinarily quickly. Ollin and Ouro, for instance, were both acquired just over a year after their official launches.
Biotechs built around China drugs are quickly being acquired or going public
Summit Therapeutics turned heads in 2024 when it claimed in a press release that a drug it had licensed from China bested the seemingly infallible cancer immunotherapy Keytruda in a head-to-head trial. Unveiled at a medical conference that September, those results cemented the drug, ivonescimab, as one of oncology research’s top prospects and fueled a frenzy to find other medicines just like it. Summit shares reached all-time highs shortly after the presentation.
Since then, Summit has struggled with the weighty expectations that emerged in the wake of that 2024 readout. While ivonescimab succeeded in additional trials and even got to market in China, it hasn’t yet proven in a global study to be the standout cancer medicine it appeared to be two-plus years ago. Investors and analysts have questioned the reliability of some of the results Summit, as well as other developers, have accumulated in studies run only in China. And this week, the Food and Drug Administration spurned Summit’s initial approval request in a form of lung cancer, sending shares back down to levels they traded at two-plus years ago.
Summit Therapeutics has lost its ivonescimab-fueled stock gains
Summit could turn things around if ivonescimab comes through in an eagerly awaited study in frontline lung cancer, which is pitting a combination of the drug and chemotherapy against the Keytruda-chemo regimen widely used in initial care. To some analysts, though, ivonescimab needs to succeed by a wide margin for Summit to truly claim victory and stay ahead of its competitors.
The FDA, for instance, made clear in its rejection letter that a modest benefit on tumor progression and a survival impact that’s only detected through after-the-fact analyses weren’t sufficient to support approval. Ivonescimab likely needs to produce a “compelling” effect on the former and a “favorable” early trend on the latter in the coming study for a chance at an accelerated approval, wrote Leerink Partners analyst Daina Graybosch.
“Without early approval, Summit risks losing its principal differentiation and valuation support — speed,” she wrote.